Pharvaris N.V. PHVS 深 沪
等待开盘 04-01 09:30:00 美东时间
28.25
+0.960
+3.52%
华盛通- 最 高28.6175
- 今 开27.73
- 成交量 56.37万股
- 最 低 27.58
- 昨 收 27.29
- 总市值 18.35亿
- 52周最高 29.797
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 12.01
- 委 比 -22.18%
- 总股本 6495.95万
- 历史最高 42.86
- 量 比 3.04
- 振 幅 3.80%
- 历史最低 1.77
- 每 手 1
- 风险率 4.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pharvaris Announces Publication Of Data From Two Randomized Phase 2 Studies, CHAPTER-1 And RAPIDe-1, Evaluating Efficacy And Safety Of Deucrictibant For Prophylaxis And On-Demand Treatment Of HAE Attacks, In The Lancet Haematology
Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAEZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris
03-20 18:53
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
RBC Capital Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $52
RBC Capital analyst Brian Abrahams initiates coverage on Pharvaris (NASDAQ:PHVS) with a Outperform rating and announces Price Target of $52.
03-09 21:35
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
Pharvaris Summarized The Presentations For The American Academy Of Allergy, Asthma & Immunology Annual Meeting For Deucrictibant For On-Demand And Prophylactic Treatment Of Bradykinin-mediated Angioedema
RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and
03-02 19:52
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
2025-12-05 08:35
美股牛股 | 机器人概念股集体爆发！iRobot涨超73%，Richtech Robotics涨超18%；医药股Capricor暴涨超371%
机器人概念股集体爆发！iRobot涨超73%，Richtech Robotics涨超18%，特朗普新政拟All in 机器人；医药股Capricor暴涨超371%，关键实验获重大突破>>
2025-12-04 15:42
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows
Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second doses and strong safety results.
2025-12-03 23:09
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
